Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

nding the current product label into adult AML. Preliminary data has been accepted for presentation at ASCO this spring and a supplemental new drug application (sNDA) for clofarabine is expected to be filed in the second half of this year. It is possible that data from this study also could be considered for part of a new filing with EMEA.

Evoltra is currently indicated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens. The withdrawal of the European application of Evoltra in adult AML has no consequences for patients enrolled in current clinical trials or compassionate use programs.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including the expected results of the data generated from clofarabine clinical trials, the presentation and use of this data to support regulatory filings, and t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... LONDON , May 27, 2015  The ... provides comprehensive understanding and unprecedented access to the ... worlds leading healthcare companies during 2014. ... gain insight into the partnering activities of the ... view all the partnering and alliances deals announced ...
(Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
(Date:5/27/2015)... VANCOUVER , May 27, 2015 /CNW/ - CQDM, ... award close to $8.5M to six (6) multi-disciplinary and ... in neuroscience within their Focus on Brain strategic initiative. ... research entities involved as in-kind contributions. This exciting announcement ... Canadian Association for Neuroscience in the presence of Inez ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
Breaking Biology Technology:Companion Diagnostics Deals and Alliances of 2014 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10Cubresa Launches Simultaneous PET/MRI Technology 2
... Asymchem Laboratories is proud to announce and welcome Dr. Guojie ... Director of Chemical Development, and Dr. Xiaojun Huang as Senior ... , ... 2010 .  He brings extensive scientific and managerial experience in pharmaceutical formulations ...
... Established ... innovations and excellence in the use of technologies, practices, and novel business strategies that ... ... 2010 -- Bio-IT World magazine announced the winners of its sixth Best Practices Awards ...
... ... year’s ISSSEEM conference will be of interest only to those who are ... meantime to live a life of happiness and value.” The International ... their 20th annual conference, Evidence-based Spirituality for the 21st Century, June 25-29, 2010 ...
Cached Biology Technology:Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang 2BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 2BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 3BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 4BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 5BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 620th Annual ISSSEEM Conference – Evidence-based Spirituality for the 21st Century 220th Annual ISSSEEM Conference – Evidence-based Spirituality for the 21st Century 3
(Date:5/28/2015)... GLEN ALLEN, Va. , May 28, 2015 ... announced the release of a new report titled ... self-healing materials (reversible polymers, inorganic capsule and vascular ... self-healing coatings) will grow to around $2.7 billion ... latest deliverable from n-tech,s extensive coverage of smart ...
(Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
(Date:5/26/2015)... 2015 Research and Markets ... the "Saudi Arabia Biometric Systems Market Forecast ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market ... projected to grow at over 22% CAGR through ... to the surging demand for better biometric technologies ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2
... currently accepted norms of biofuel production. A commentary published ... of greenhouse gas (GHGs) emissions from bioenergy production are ... of the benefits of biofuels compared to fossil fuels. ... Analysis models of bioenergy production. Life Cycle Analysis (LCA) ...
... be as common as initial HIV infection and is ... study led by researchers at the Johns Hopkins Bloomberg ... Allergy and Infectious Diseases (NIAID). In the first large-scale ... researchers examined the rate of superinfection among a community ...
... with discarded plastics, scientists have been working to produce ... Tel Aviv University researcher is giving the quest for ... making them tougher than ever before. Prof. ... a super-strength polypropylene one of the world,s most ...
Cached Biology News:Environmental benefit of biofuels is overestimated, new study reveals 2New data suggests HIV superinfection rate comparable to initial HIV infection 2New data suggests HIV superinfection rate comparable to initial HIV infection 3Steel-strength plastics -- and green, too! 2Steel-strength plastics -- and green, too! 3
Sheep Serum US Origin...
Human LAIR2 Biotinylated Affinity Purified PAb...
... the mycobacteria found in Complete Freund's Adjuvant so ... Freund's Adjuvant is used for ... to produce water-in-oil emulsions of immunogens. ... antibody responses which can be attributed to the ...
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: